{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:28:21Z","timestamp":1793824101140,"version":"4.6.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1012570","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000}}],"reference-count":78,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Resistance to therapy is a major clinical obstacle to treatment of cancer and communicable diseases. Drug selection in treatment of patients where the disease is showing resistance to therapy is often guided by IC<jats:sub>50<\/jats:sub> or fold-IC<jats:sub>50<\/jats:sub> values. In this work, through a model of the treatment of chronic myeloid leukaemia (CML), we contest using fold-IC<jats:sub>50<\/jats:sub> values as a guide for treatment selection. CML is a blood cancer that is treated with Abl1 inhibitors, and is often seen as a model for targeted therapy and drug resistance. Resistance to the first-line treatment occurs in approximately one in four patients. The most common cause of resistance is mutations in the Abl1 enzyme. Different mutant Abl1 enzymes show resistance to different Abl1 inhibitors and the mechanisms that lead to resistance for various mutation and inhibitor combinations are not fully known, making the selection of Abl1 inhibitors for treatment a difficult task. We developed a model based on information of catalysis, inhibition and pharmacokinetics, and applied it to study the effect of three Abl1 inhibitors on mutants of the Abl1 enzyme. From this model, we show that the relative decrease of product formation rate (defined in this work as \u201cinhibitory reduction prowess\u201d) is a better indicator of resistance than an examination of the size of the product formation rate or fold-IC<jats:sub>50<\/jats:sub> values for the mutant. We also examine current ideas and practices that guide treatment choice and suggest a new parameter for selecting treatments that could increase the efficacy and thus have a positive impact on patient outcomes.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1012570","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:45:03Z","timestamp":1731005103000},"page":"e1012570","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Beyond IC50\u2014A computational dynamic model of drug resistance in enzyme inhibition treatment"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-6226","authenticated-orcid":true,"given":"J.","family":"Roadnight Sheehan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-6811","authenticated-orcid":true,"given":"Astrid S.","family":"de Wijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales Souza","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3104","authenticated-orcid":true,"given":"Ran","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"issue":"8","key":"pcbi.1012570.ref001","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-005-1039-z","article-title":"Chronic myeloid leukemia: a model for oncology","volume":"84","author":"R Hehlmann","year":"2005","journal-title":"Annals of Hematology"},{"issue":"1","key":"pcbi.1012570.ref002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/ehm.09.66","article-title":"Targeting the bcr\u2013abl tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer","volume":"3","author":"A Z\u00e1me\u010dn\u00edkova","year":"2010","journal-title":"Expert Review of Hematology"},{"issue":"17","key":"pcbi.1012570.ref003","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"CL Sawyers","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"48","key":"pcbi.1012570.ref004","article-title":"The philadelphia chromosome in leukemogenesis","volume":"35","author":"Z Kang","year":"2016","journal-title":"Chinese Journal of Cancer"},{"issue":"1","key":"pcbi.1012570.ref005","article-title":"The philadelphia chromosome in leukemogenesis","volume":"35","author":"AS Advani","year":"2016","journal-title":"Chinese Journal of Cancer"},{"issue":"1","key":"pcbi.1012570.ref006","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/asheducation-2009.1.453","article-title":"Initial treatment for patients with cml","volume":"2009","author":"JM Goldman","year":"2009","journal-title":"Hematology"},{"key":"pcbi.1012570.ref007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"L Caldemeyer","year":"2016","journal-title":"Current Hematologic Malignancy Reports"},{"key":"pcbi.1012570.ref008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of cml","volume":"94","author":"B Chereda","year":"2015","journal-title":"Annals of Hematology"},{"issue":"397","key":"pcbi.1012570.ref009","article-title":"The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib","volume":"20","author":"HJG Lindstr\u00f6m","year":"2020","journal-title":"BMC Cancer"},{"key":"pcbi.1012570.ref010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.leu.2403664","article-title":"Monitoring patients in complete cytogenetic remission after treatment of cml in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse","volume":"19","author":"D Marin","year":"2005","journal-title":"Leukemia"},{"issue":"11","key":"pcbi.1012570.ref011","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V112.11.182.182","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (cml) in early chronic phase (cml-cp)","volume":"112","author":"J Cortes","year":"2008","journal-title":"Blood"},{"issue":"21","key":"pcbi.1012570.ref012","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood.V120.21.3749.3749","article-title":"The pace study group; efficacy and safety of ponatinib according to prior approved tyrosine kinase inhibitor (tki) therapy in patients with chronic myeloid leukemia in chronic phase (cp-cml): Results from the pace trial","volume":"120","author":"D Kim","year":"2012","journal-title":"Blood"},{"issue":"508","key":"pcbi.1012570.ref013","article-title":"Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia","volume":"19","author":"HJG Lindstr\u00f6m","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"pcbi.1012570.ref014","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to bcr-abl1-targeted therapies","volume":"37","author":"TP Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"pcbi.1012570.ref015","doi-asserted-by":"crossref","DOI":"10.1038\/srep08190","article-title":"Drug target optimization in chronic myeloid leukemia using innovative computational platform","volume":"5","author":"R Chuang","year":"2015","journal-title":"Scientific Reports"},{"key":"pcbi.1012570.ref016","volume-title":"Hematologic Malignancies","author":"A Lovell","year":"2021"},{"issue":"8","key":"pcbi.1012570.ref017","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1039\/D2CP05549J","article-title":"Resistance to a tyrosine kinase inhibitor mediated by changes to the conformation space of the kinase","volume":"25","author":"TS Freire","year":"2023","journal-title":"Physical Chemistry Chemical Physics"},{"issue":"1","key":"pcbi.1012570.ref018","doi-asserted-by":"crossref","first-page":"188666","DOI":"10.1016\/j.bbcan.2021.188666","article-title":"The molecular mechanisms behind activation of flt3 in acute myeloid leukemia and resistance to therapy by selective inhibitors","volume":"1877","author":"R Friedman","year":"2022","journal-title":"Biochimica et Biophysica Acta (BBA)\u2014Reviews on Cancer"},{"issue":"4","key":"pcbi.1012570.ref019","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.bbagen.2019.01.011","article-title":"The catalytic activity of abl1 single and compound mutations: Implications for the mechanism of drug resistance mutations in chronic myeloid leukaemia","volume":"1863","author":"PS Georgouliaa","year":"2019","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"pcbi.1012570.ref020","article-title":"Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: Results from the euro-ski trial","author":"F Efficace","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"pcbi.1012570.ref021","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European leukemianet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"A Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"pcbi.1012570.ref022","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/9781394180486.ch6","article-title":"Chronic myelogenous leukemia","author":"H Kantarjian","year":"2024","journal-title":"Molecular Hematology"},{"key":"pcbi.1012570.ref023","article-title":"Chronic myeloid leukemia: Modern therapies, current challenges and future directions","volume":"49","author":"AEG Osman","year":"2021","journal-title":"Blood Reviews"},{"issue":"10","key":"pcbi.1012570.ref024","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1177\/1087057110384402","article-title":"How desirable are your IC50s?: A way to enhance screening-based decision making","volume":"15","author":"GV Paolini","year":"2010","journal-title":"SLAS Discovery"},{"key":"pcbi.1012570.ref025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.toxlet.2018.12.004","article-title":"How reliable are in vitro IC50 values? values vary with cytotoxicity assays in human glioblastoma cells","volume":"302","author":"E Damiani","year":"2019","journal-title":"Toxicology Letters"},{"issue":"4","key":"pcbi.1012570.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061007","article-title":"Comparability of mixed IC50 data\u2014a statistical analysis","volume":"8","author":"T Kalliokoski","year":"2013","journal-title":"PLoS ONE"},{"issue":"5","key":"pcbi.1012570.ref027","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1021\/acs.jcim.4c00049","article-title":"Combining IC50 or Ki values from different sources is a source of significant noise","volume":"64","author":"GA Landrum","year":"2024","journal-title":"Journal of Chemical Information and Modeling"},{"issue":"11","key":"pcbi.1012570.ref028","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2174\/156802612800672844","article-title":"The IC50 concept revisited","volume":"12","author":"GW Caldwell","year":"2012","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"1","key":"pcbi.1012570.ref029","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.24247","article-title":"Chronic myeloid leukemia: Second-line drugs of choice","volume":"91","author":"C Gambacorti-Passerini","year":"2015","journal-title":"American Journal of Hematology"},{"issue":"7","key":"pcbi.1012570.ref030","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"T O\u2019Hare","year":"2007","journal-title":"Blood"},{"issue":"6","key":"pcbi.1012570.ref031","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1634\/theoncologist.2010-0388","article-title":"Choosing the best second\u2010line tyrosine kinase inhibitor in imatinib\u2010resistant chronic myeloid leukemia patients harboring bcr\u2010abl kinase domain mutations: How reliable is the IC50?","volume":"16","author":"S Soverini","year":"2011","journal-title":"The Oncologist"},{"issue":"11","key":"pcbi.1012570.ref032","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood.V110.11.1941.1941","article-title":"Event-free survival in patients (pts) with chronic myeloid leukemia (cml) treated with 2nd generation tyrosine kinase inhibitors (tki) after imatinib failure is dependent on the in vitro sensitivity of bcr-abl kinase domain (kd) mutations","volume":"110","author":"E Jabbour","year":"2007","journal-title":"Blood"},{"issue":"19","key":"pcbi.1012570.ref033","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2012-08-452409","article-title":"Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to abl kinase inhibitors in chronic myeloid leukemia","volume":"122","author":"V Vainstein","year":"2013","journal-title":"Blood"},{"issue":"1","key":"pcbi.1012570.ref034","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, nccn clinical practice guidelines in oncology","volume":"22","author":"NP Shah","year":"2024","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"pcbi.1012570.ref035","volume-title":"Hematologic Malignancies","author":"N Shanmuganathan","year":"2021"},{"issue":"8","key":"pcbi.1012570.ref036","doi-asserted-by":"crossref","first-page":"102238","DOI":"10.1016\/j.jbc.2022.102238","article-title":"Allosteric enhancement of the bcr-abl1 kinase inhibition activity of nilotinib by cobinding of asciminib","volume":"298","author":"B Oruganti","year":"2022","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"pcbi.1012570.ref037","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1021\/acs.jctc.1c00505","article-title":"Activation of abl1 kinase explored using well-tempered metadynamics simulations on an essential dynamics sampled path","volume":"17","author":"B Oruganti","year":"2021","journal-title":"Journal of Chemical Theory and Computation"},{"issue":"5","key":"pcbi.1012570.ref038","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.molonc.2013.06.001","article-title":"Through the open door: Preferential binding of dasatinib to the active form of bcr-abl unveiled by in silico experiments","volume":"7","author":"E Laurini","year":"2013","journal-title":"Molecular Oncology"},{"issue":"26","key":"pcbi.1012570.ref039","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of abl kinase-inhibitor complexes determined by nmr substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"N Vajpai","year":"2008","journal-title":"Journal of Biological Chemistry"},{"issue":"26","key":"pcbi.1012570.ref040","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1021\/acs.jpcb.6b01911","article-title":"Statistical mechanics of allosteric enzymes","volume":"120","author":"T Einav","year":"2016","journal-title":"The Journal of Physical Chemistry B"},{"issue":"7","key":"pcbi.1012570.ref041","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/2472555217695080","article-title":"A high-throughput method for measuring drug residence time using the transcreener adp assay","volume":"22","author":"M Kumar","year":"2017","journal-title":"SLAS Discovery"},{"issue":"11","key":"pcbi.1012570.ref042","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived bcr\/abl mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"S Redaelli","year":"2012","journal-title":"American Journal of Hematology"},{"issue":"3","key":"pcbi.1012570.ref043","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"Bcr-abl1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in ph chromosome-positive leukemia","volume":"26","author":"MS Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"pcbi.1012570.ref044","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/prot.25368","article-title":"The molecular mechanism behind resistance of the kinase flt3 to the inhibitor quizartinib","volume":"85","author":"R Friedman","year":"2017","journal-title":"Proteins: Structure, Function, and Bioinformatics"},{"issue":"11","key":"pcbi.1012570.ref045","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (bms-354825) bound to activated abl kinase domain elucidates its inhibitory activity against imatinib-resistant abl mutants","volume":"66","author":"JS Tokarski","year":"2006","journal-title":"Cancer Research"},{"issue":"1","key":"pcbi.1012570.ref046","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"SW Cowan-Jacob","year":"2006","journal-title":"Acta Crystallographica Section D Biological Crystallography"},{"key":"pcbi.1012570.ref047","unstructured":"Dassault Syst\u00e8mes BIOVIA. Biovia discovery studio. version 2021. San Diego: Dassault Syst\u00e8mes, 2022."},{"key":"pcbi.1012570.ref048","unstructured":"SWISS. Model interactive workspace."},{"key":"pcbi.1012570.ref049","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1-2","author":"MJ Abraham","year":"2015","journal-title":"SoftwareX"},{"issue":"1-3","key":"pcbi.1012570.ref050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0010-4655(95)00042-E","article-title":"Gromacs: A message-passing parallel molecular dynamics implementation","volume":"91","author":"HJC Berendsen","year":"1995","journal-title":"Computer Physics Communications"},{"issue":"16","key":"pcbi.1012570.ref051","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"Gromacs: Fast, flexible, and free","volume":"26","author":"D Van Der Spoel","year":"2005","journal-title":"Journal of Computational Chemistry"},{"issue":"2","key":"pcbi.1012570.ref052","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1021\/acs.jcim.6b00498","article-title":"pmx webserver: A user friendly interface for alchemistry","volume":"57","author":"V Gapsys","year":"2017","journal-title":"Journal of Chemical Information and Modeling"},{"issue":"5","key":"pcbi.1012570.ref053","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/jcc.23804","article-title":"pmx: Automated protein structure and topology generation for alchemical perturbations","volume":"36","author":"V Gapsys","year":"2014","journal-title":"Journal of Computational Chemistry"},{"issue":"2","key":"pcbi.1012570.ref054","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"WL Jorgensen","year":"1983","journal-title":"The Journal of Chemical Physics"},{"issue":"12","key":"pcbi.1012570.ref055","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh ewald: An nlog(n) method for ewald sums in large systems","volume":"98","author":"T Darden","year":"1993","journal-title":"The Journal of Chemical Physics"},{"issue":"1","key":"pcbi.1012570.ref056","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/ct700200b","article-title":"P-lincs: A parallel linear constraint solver for molecular simulation","volume":"4","author":"B Hess","year":"2007","journal-title":"Journal of Chemical Theory and Computation"},{"issue":"12","key":"pcbi.1012570.ref057","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"Lincs: A linear constraint solver for molecular simulations","volume":"18","author":"B Hess","year":"1997","journal-title":"Journal of Computational Chemistry"},{"issue":"8","key":"pcbi.1012570.ref058","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jcc.540130805","article-title":"Settle: An analytical version of the shake and rattle algorithm for rigid water models","volume":"13","author":"S Miyamoto","year":"1992","journal-title":"Journal of Computational Chemistry"},{"issue":"1","key":"pcbi.1012570.ref059","doi-asserted-by":"crossref","first-page":"014101","DOI":"10.1063\/1.2408420","article-title":"Canonical sampling through velocity rescaling","volume":"126","author":"G Bussi","year":"2007","journal-title":"The Journal of Chemical Physics"},{"issue":"8","key":"pcbi.1012570.ref060","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1063\/1.448118","article-title":"Molecular dynamics with coupling to an external bath","volume":"81","author":"HJC Berendsen","year":"1984","journal-title":"The Journal of Chemical Physics"},{"issue":"12","key":"pcbi.1012570.ref061","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: A new molecular dynamics method","volume":"52","author":"M Parrinello","year":"1981","journal-title":"Journal of Applied Physics"},{"issue":"10","key":"pcbi.1012570.ref062","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.bpj.2010.01.051","article-title":"Protein thermostability calculations using alchemical free energy simulations","volume":"98","author":"D Seeliger","year":"2010","journal-title":"Biophysical Journal"},{"issue":"2","key":"pcbi.1012570.ref063","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0021-9991(76)90078-4","article-title":"Efficient estimation of free energy differences from monte carlo data","volume":"22","author":"CH Bennett","year":"1976","journal-title":"Journal of Computational Physics"},{"key":"pcbi.1012570.ref064","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-16-8950-5","volume-title":"Pharmacokinetics: Basics to Applications, chapter 1.1.2 Multiple-Dose Regimen","author":"B Mukherjee","year":"2022"},{"key":"pcbi.1012570.ref065","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"B Peng","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"issue":"1","key":"pcbi.1012570.ref066","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/jcpt.13257","article-title":"Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance","volume":"46","author":"M Abumiya","year":"2020","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"2","key":"pcbi.1012570.ref067","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2010.06.010","article-title":"Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma","volume":"97","author":"C Li","year":"2010","journal-title":"Radiotherapy and Oncology"},{"key":"pcbi.1012570.ref068","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s13318-015-0292-3","article-title":"Population pharmacokinetic analysis of the oral absorption process and explaining intra-subject variability in plasma exposures of imatinib in healthy volunteers","volume":"41","author":"A Golabchifar","year":"2016","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"issue":"4","key":"pcbi.1012570.ref069","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jcph.1990","article-title":"Population pharmacokinetics of ponatinib in healthy adult volunteers and patients with hematologic malignancies and model-informed dose selection for pediatric development","volume":"62","author":"MJ Hanley","year":"2021","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"11","key":"pcbi.1012570.ref070","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/0091270008320604","article-title":"Importance of characterizing determinants of variability in exposure: Application to dasatinib in subjects with chronic myeloid leukemia","volume":"48","author":"G Dai","year":"2013","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"2","key":"pcbi.1012570.ref071","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/CRST.CRST_98_19","article-title":"Ponatinib: A drug review","volume":"2","author":"H Jain","year":"2019","journal-title":"Cancer Research, Statistics, and Treatment"},{"key":"pcbi.1012570.ref072","first-page":"205","article-title":"Chapter four\u2014dasatinib","volume":"39","author":"HM Korashy","year":"2014","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"issue":"9","key":"pcbi.1012570.ref073","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"JE Cortes","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"pcbi.1012570.ref074","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of dasatinib","volume":"59","author":"D Lev\u00eaque","year":"2020","journal-title":"Clinical Pharmacokinetics"},{"issue":"10","key":"pcbi.1012570.ref075","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/17474086.2016.1232163","article-title":"Ponatinib in the therapy of chronic myeloid leukemia","volume":"9","author":"PM Martell","year":"2016","journal-title":"Expert Review of Hematology"},{"issue":"2","key":"pcbi.1012570.ref076","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-5193(05)80266-8","article-title":"Cellular concentrations of enzymes and their substrates","volume":"143","author":"KR Albe","year":"1990","journal-title":"Journal of Theoretical Biology"},{"key":"pcbi.1012570.ref077","unstructured":"Moran, U. Cellular concentration of glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate kinase."},{"key":"pcbi.1012570.ref078","volume-title":"Cell and Molecular Biology for Non-Biologists: A short introduction into key biological concepts, chapter 4.3.1 Post-Translational Modifications","author":"L Adlung","year":"2021"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1012570","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T18:42:26Z","timestamp":1732041746000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012570"}},"subtitle":[],"editor":[{"given":"James","family":"Gallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1012570","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1012570","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}